Evgen Pharma (LON:EVG)

Evgen Pharma (LON:EVG)


Share Price
15.00 p
Change
-1.75 (-10.45 %)
Market Cap
£14.84 m
Proactive Investors - Run By Investors For Investors

Evgen Pharma

Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions.

EPIC: EVG
Market: AIM:EVG
52-week High/Low: 27.60p / 12.15p
Sector: Pharma & Biotech
Market Cap: 14.84M
Website: evgen.com
col 3
col 4
col 5
col 6

Evgen Pharma Timeline

CN Video

Riccardo Lowi discusses Evgen Pharma

Riccardo Lowi analyst at Capital Network talks through Evgen Pharma that has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug.
Sulforaphane, a natural compound first isolated from a precursor in Brassica plants, has shown therapeutic potential, but has also proven too unstable to be manufactured as a drug on commercial scale. Evgen Pharma (LON:EVG) has developed a proprietary technology - Sulforadex® - that allows the synthesis of...
For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use